Please upgrade your browser.
A national independent market research organization is recruiting advanced and metastatic kidney cancer patients
Participants in this market research will be asked to provide feedback on their own experiences with advanced / metastatic kidney cancer and its treatment.
Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus
Supported, in part, by Kidney Cancer Association’s funding supporting this ASCO Merit Award. Samples from 79 of 94 patients were successfully sequenced and were included in the analysis.
Government regulators are backing down from many of their toughest requirements for doctors' and hospitals' use of digital medical records, just as Congress is stepping up its oversight of issues with the costly technology.
... it may be a better way of testing for kidney cancer than a biopsy, which can only provide results for the portion of tissue that was removed, not the entire organ.
More than 20 percent of Wilms’ tumor survivors who had radiation to the chest developed breast cancer by age 40, compared to just .03 percent who didn’t have radiation.
KIDNEY CANCER EDUCATION WORKSHOP: Free Event for Patients, Survivors and Caregivers in Seattle on June 20, 2015
The Kidney Cancer Association (KCA) is holding a free education workshop to inform patients, survivors and their families about available treatment options and information needed to navigate an advanced kidney cancer diagnosis.
AGS-003 for metastatic renal cell carcinoma ((mRCC)) in Phase III with the full patient enrollment expected in Q2-2014. The final results should come out in the second half of 2016. The primary endpoint of the study is the overall survival.
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
Tumors gain survival advantage by reprogramming their metabolism according to an international team of scientists, led by UC Davis nephrologist Robert Weiss...
Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.
|Powered by NeonCRM|